109 related articles for article (PubMed ID: 25267886)
1. Potential therapeutic strategy to treat substance abuse related disorders.
Chang SL
J Food Drug Anal; 2013 Dec; 21(4):S25-S26. PubMed ID: 25267886
[TBL] [Abstract][Full Text] [Related]
2. HIV: seek, test, treat, and retain.
Normand J; Montaner J; Fang CT; Wu Z; Chen YM
J Food Drug Anal; 2013 Dec; 21(4):S4-S6. PubMed ID: 25278735
[TBL] [Abstract][Full Text] [Related]
3. Brain Abnormalities in HIV and Stimulant Users: Interventions and Prevention.
Chang L; Shoptaw S; Normand J
J Food Drug Anal; 2013 Dec; 21(4):S7-S9. PubMed ID: 25264417
[TBL] [Abstract][Full Text] [Related]
4. Genetics and pharmacogenetics of substance use disorders.
Tao PL; Chen LS; Chen CK; Liu YL
J Food Drug Anal; 2013 Dec; 21(4):S23-S24. PubMed ID: 25267885
[TBL] [Abstract][Full Text] [Related]
5. Prevention, family, and community.
Yang SL; Rohrbach LA; Daley D
J Food Drug Anal; 2013 Dec; 21(4):S16-S18. PubMed ID: 25264416
[TBL] [Abstract][Full Text] [Related]
6. Medication-assisted therapy for opioid addiction.
Tai B; Saxon AJ; Ling W
J Food Drug Anal; 2013 Dec; 21(4):S13-S15. PubMed ID: 25264415
[TBL] [Abstract][Full Text] [Related]
7. Harm reduction.
Normand J; Li JH; Thomson N; Jarlais DD
J Food Drug Anal; 2013 Oct; 21(4):S10-S12. PubMed ID: 25278732
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of dual substance abuse and dependence.
Kenna GA; Nielsen DM; Mello P; Schiesl A; Swift RM
CNS Drugs; 2007; 21(3):213-37. PubMed ID: 17338593
[TBL] [Abstract][Full Text] [Related]
9. Opportunities for the development of neuroimmune therapies in addiction.
Ray LA; Roche DJ; Heinzerling K; Shoptaw S
Int Rev Neurobiol; 2014; 118():381-401. PubMed ID: 25175870
[TBL] [Abstract][Full Text] [Related]
10. Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence.
Walker BM; Valdez GR; McLaughlin JP; Bakalkin G
Alcohol; 2012 Jun; 46(4):359-70. PubMed ID: 22459870
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
12. The comparative effectiveness of Integrated treatment for Substance abuse and Partner violence (I-StoP) and substance abuse treatment alone: a randomized controlled trial.
Kraanen FL; Vedel E; Scholing A; Emmelkamp PM
BMC Psychiatry; 2013 Jul; 13():189. PubMed ID: 24059784
[TBL] [Abstract][Full Text] [Related]
13. The development of antibody-based immunotherapy for methamphetamine abuse: immunization, and virus-mediated gene transfer approaches.
Chen YH; Chen CH
Curr Gene Ther; 2013 Feb; 13(1):39-50. PubMed ID: 23157545
[TBL] [Abstract][Full Text] [Related]
14. Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat.
Liu X; Chang L; Vigorito M; Kass M; Li H; Chang SL
J Neuroimmune Pharmacol; 2009 Sep; 4(3):309-16. PubMed ID: 19444617
[TBL] [Abstract][Full Text] [Related]
15. Comment on "Transpedicle body augmenter in painful osteoporotic compression fractures" (Kung-Chia Li, Anna F.-Y. Li, Ching-Hsiang Hsieh, Hsiang-Ho Chen).
Heini PF
Eur Spine J; 2007 May; 16(5):599-600. PubMed ID: 16964507
[No Abstract] [Full Text] [Related]
16. [Current situation of substance abuse/dependence in psychiatric hospital settings].
Ozaki S
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2004 Feb; 39(1):35-40. PubMed ID: 15058092
[TBL] [Abstract][Full Text] [Related]
17. Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence.
Coller JK; Hutchinson MR
Pharmacol Ther; 2012 May; 134(2):219-45. PubMed ID: 22316499
[TBL] [Abstract][Full Text] [Related]
18. [GC-MS analysis of methamphetamine and amphetamine in hair of Thai drug addicts].
Ando E; Hayashida M; Nihira M; Yamada T; Ohno Y
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2004 Jun; 39(3):168-79. PubMed ID: 15291265
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].
Michel L; Lions C; Winnock M; Lang JP; Loko MA; Rosenthal E; Marchou B; Valantin MA; Morlat P; Roux P; Sogni P; Spire B; Poizot-Martin I; Lacombe K; Lascoux-Combe C; Duvivier C; Neau D; Dabis F; Salmon-Ceron D; Carrieri MP;
HIV Med; 2016 Nov; 17(10):758-765. PubMed ID: 27187027
[TBL] [Abstract][Full Text] [Related]
20. Are therapeutic vaccines an answer to the global problem of drug and alcohol abuse?
Brashier DB; Sharma AK; Akhoon N
Indian J Pharmacol; 2016; 48(5):487-489. PubMed ID: 27721531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
